Clinical Trial Update: Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) Recurrence [Phase 4]

View source ↗

Summary

A Phase 4 trial update suggests tenofovir alafenamide (TAF) reduces recurrence risk of hepatocellular carcinoma after curative treatment in patients with low HB…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tenofovir alafenamide (tenofovir alafenamide)

Snippet

Sponsor: Taipei Veterans General Hospital, Taiwan | Conditions: HCC Patients After Curative Treatment With Low HBV Viral Load | Phase 4 | Status: UNKNOWN